Clinical Trials in Renal Cell Carcinoma
Dr. Brian Rini and Dr. David F. McDermott discuss two different clinical trials for #KidneyCancer patients.12/11/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 11, 2018 Category: Urology & Nephrology Source Type: news

An overview of renal cell carcinoma
RCC is the seventh leading cause of cancer deaths in the U.S. Check out this article for an overview of the condition.12/10/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 10, 2018 Category: Urology & Nephrology Source Type: news

miR ‑122 promotes proliferation and invasion of clear cell renal cell carcinoma by suppressing Forkhead box O3
MicroRNAs (miRNAs) serve an important role in renal cancer, but renal cancer miRNA expression data remains inconsistent.12/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 5, 2018 Category: Urology & Nephrology Source Type: news

Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience
Sunitinib treatment has acceptable efficacy and safety profile in Malaysian mRCC patients. The MSKCC and IMDC factors are relevant for predicting survival in our patient cohort while HFS is a promising prognostic predictor which warrants further investigation.12/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 5, 2018 Category: Urology & Nephrology Source Type: news

Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma
An analysis showed that fatty acid binding protein 7 (FABP7) has the highest mean differential overexpression in ccRCC compared to normal kidney.11/21/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 21, 2018 Category: Urology & Nephrology Source Type: news

Epidemiology of Renal Cell Carcinoma
Despite the improvement in renal cell carcinoma (RCC) diagnosis and management observed during the last 2 decades, RCC remains one of the most lethal urological malignancies. With the expansion of routine imaging for many disorders, an increasing number of patients who harbour RCC are identified incidentally.11/20/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 20, 2018 Category: Urology & Nephrology Source Type: news

Trials Presented at ESMO 2018
In patients with previously untreated advanced renal cell carcinoma (RCC) whose tumors were positive for the PD-L1 checkpoint, a combination of the checkpoint inhibitor avelumab and the tyrosine kinase inhibitor (TKI) axitinib increased the median PFS from 8.4 months to 13.8 months when compared with the TKI sunitinib (HR 0.69; P=0.0001).11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and survival, and additionally plays an important role in immune regulation. Since mTOR inhibitors were shown to benefit immunosuppressive regulatory T-cell (Treg) expansion, this might suppress antitumor immune responses. Metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

CIP2A Promotes Proliferation, Invasion and Chemoresistance to Cisplatin in Renal Cell Carcinoma
CIP2A is a well-known oncoprotein whose expression is elevated in multiple human solid tumor types. However, its role in renal cell carcinoma (RCC) development is poorly understood.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence post-nephrectomy.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Scientists identify potential new treatment strategy for kidney cancer
Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

Scientists identify potential new treatment strategy for kidney cancer
(eLife) Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2018 Category: Cancer & Oncology Source Type: news

MDACC 2018: Debate: What is the Best Front-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma?
In this article, Dr. Gao defends Nivolumab plus ipilimumab as the best front-line systemic therapy for mRCC.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news

MDACC 2018: Debate: Is There Still a Role for Cytoreductive Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma?
Dr. Jose Karam explains the role of cytoreductive nephrectomies when patients have metastatic kidney cancer.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news

Systemic Therapy Options for Renal Cell Carcinoma
Monty Pal and Charles Ryan discuss systemic therapeutic options and current clinical trials in the renal cell carcinoma space.11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news